A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache

• Status: Completed
• Trial end date: 2018-02-12
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Participants with a history of migraine of at least 1 year prior to enrollment.

• Migraine onset prior to age 50.

Exclusion Criteria:

• Current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device.

• Current use or any prior exposure to any CGRP antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).

• History of migraine subtypes including hemiplegic migraine, ophthalmoplegic migraine, and basilar-type migraine.

• Have a history or presence of other medical illness that indicates a medical problem that would preclude study participation.

• Failure to respond to more than two adequately dosed effective migraine prevention treatments.

• Evidence of significant active psychiatric disease, in the opinion of the investigator.

• Women who are pregnant or nursing.